Table 1.3
(continued)
Experimental model
The form of soya bean
Dose and route of
administration
Investigation
Major
finding/s
Reference
Sprague-Dawley rats
Phenolic-rich soy husk
powder extract (SHPE)
250 mg SHPE/kg BW or
500 mg SHPE/kg BW
Assay of blood glucose, lipid
metabolism parameters
Hypoglycemic and
antiadipogenic
Tan et al.
(2019)
Human (diabetic)
Soy protein with or
without isoflavones (SPI,
SP)
7.5 g (15 g daily) of 70% isolated soy protein powder with
or without added isoflavones
(Solgen 16 mg per bar, 32 mg
in total daily) for 8 weeks
Assay of blood glucose, lipid
metabolism parameters
Weight and body fat
reduction along with
hypolipidemic effect
Konya et al.
(2019)
Goto-Kakizaki rats
Soy isoflavones (SIF)
SIF (150 mg/kg BW) for
16 weeks
Assay of blood glucose, lipid
metabolism parameters
Hypoglycemic
Jin et al.
(2018)
Wistar rats
Soy isoflavones
80 mg/kg BW/d for 4 weeks
Assay of plasma insulin, blood
glucose, and hepatic glycogen
Antidiabetic
and hypolipidemic
Hamden
et al. (2011)
In vitro
–
Analysis of insulinosecretory effect of isoflavones
and
α-amylase inhibitory
activity
Sprague-Dawley rats
Soy hull soluble dietary
fiber (SHSDF)
4% of SHSDF for 4 weeks
Hypocholesterolemic
Activity assay
Hypocholesterolemic Liu et al.
(2016)
In vitro
–
Assay of in vitro cholesterolbinding capacity, bile acidbinding capacity, and glucose
dialysis retardation index
Sprague-Dawley rats
Soy isoflavones
0.2% soy isoflavones rich
powder for 5 weeks
Assay of blood lipid parameters and antioxidant enzymes
Antioxidant and
hypocholesterolemic
Kawakami
et al. (2004)
Wistar adult rats
Soybean
β-conglycinin
(>90% protein, 0.4%
isoflavone, and 0.2%
saponin)
20% soybean
β-conglycinin
for 4 weeks
Assay of carbohydrate and
lipid metabolism parameters
Hypolipidemic
Inoue et al.
(2015)
14
R. Modgil et al.